Dane Leone
Stock Analyst at Raymond James
(1.29)
# 3,457
Out of 4,876 analysts
82
Total ratings
38.1%
Success rate
-5.89%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.68 | +486.60% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.26 | +444.79% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $128.11 | -21.94% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $37.34 | -19.66% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $518.73 | +83.14% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.71 | +662.46% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $44.42 | +3.56% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $28.08 | +145.77% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $3.29 | +782.80% | 2 | Apr 19, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $2.55 | +213.73% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $9.20 | +52.26% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $8.09 | +617.38% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $17.01 | +311.52% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.22 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $32.95 | +91.20% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $46.24 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.18 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $40.00 | +62.50% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.18 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $276.57 | -7.80% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $2.92 | +997.77% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $152.23 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.68
Upside: +486.60%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.26
Upside: +444.79%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $128.11
Upside: -21.94%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $37.34
Upside: -19.66%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $518.73
Upside: +83.14%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.71
Upside: +662.46%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $44.42
Upside: +3.56%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $28.08
Upside: +145.77%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.29
Upside: +782.80%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.55
Upside: +213.73%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $9.20
Upside: +52.26%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $8.09
Upside: +617.38%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $17.01
Upside: +311.52%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.22
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $32.95
Upside: +91.20%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $46.24
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.18
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $40.00
Upside: +62.50%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $9.18
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $276.57
Upside: -7.80%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $2.92
Upside: +997.77%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $152.23
Upside: -